FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:AKAP8-OSGEPL1

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: AKAP8-OSGEPL1
FusionPDB ID: 3381
FusionGDB2.0 ID: 3381
HgeneTgene
Gene symbol

AKAP8

OSGEPL1

Gene ID

10270

64172

Gene nameA-kinase anchoring protein 8O-sialoglycoprotein endopeptidase like 1
SynonymsAKAP 95|AKAP-8|AKAP-95|AKAP95OSGEPL|Qri7
Cytomap

19p13.12

2q32.2

Type of geneprotein-codingprotein-coding
DescriptionA-kinase anchor protein 8A kinase (PRKA) anchor protein 8A-kinase anchor protein, 95kDaprobable tRNA N6-adenosine threonylcarbamoyltransferase, mitochondrialN6-L-threonylcarbamoyladenine synthaseO-sialoglycoprotein endopeptidase-like protein 1probable O-sialoglycoprotein endopeptidase 2probable tRNA threonylcarbamoyladenosine biosynthes
Modification date2020031320200313
UniProtAcc

Q9ULX6

Main function of 5'-partner protein: FUNCTION: Could play a role in constitutive transport element (CTE)-mediated gene expression by association with DHX9. Increases CTE-dependent nuclear unspliced mRNA export (PubMed:10748171, PubMed:11402034). Proposed to target PRKACA to the nucleus but does not seem to be implicated in the binding of regulatory subunit II of PKA (PubMed:10761695, PubMed:11884601). May be involved in nuclear envelope breakdown and chromatin condensation. May be involved in anchoring nuclear membranes to chromatin in interphase and in releasing membranes from chromating at mitosis (PubMed:11034899). May regulate the initiation phase of DNA replication when associated with TMPO isoform Beta (PubMed:12538639). Required for cell cycle G2/M transition and histone deacetylation during mitosis. In mitotic cells recruits HDAC3 to the vicinity of chromatin leading to deacetylation and subsequent phosphorylation at 'Ser-10' of histone H3; in this function seems to act redundantly with AKAP8 (PubMed:16980585). May be involved in regulation of pre-mRNA splicing (PubMed:17594903). {ECO:0000269|PubMed:10748171, ECO:0000269|PubMed:11034899, ECO:0000269|PubMed:11402034, ECO:0000269|PubMed:11884601, ECO:0000269|PubMed:12538639, ECO:0000269|PubMed:16980585, ECO:0000305|PubMed:10761695}.; FUNCTION: (Microbial infection) In case of EBV infection, may target PRKACA to EBNA-LP-containing nuclear sites to modulate transcription from specific promoters. {ECO:0000269|PubMed:11884601}.; FUNCTION: (Microbial infection) Can synergize with DHX9 to activate the CTE-mediated gene expression of type D retroviruses. {ECO:0000269|PubMed:11402034}.; FUNCTION: (Microbial infection) In case of HIV-1 infection, involved in the DHX9-promoted annealing of host tRNA(Lys3) to viral genomic RNA as a primer in reverse transcription; in vitro negatively regulates DHX9 annealing activity. {ECO:0000269|PubMed:25034436}.
.
Ensembl transtripts involved in fusion geneENST idsENST00000269701, ENST00000264151, 
ENST00000519810, ENST00000522700, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score13 X 14 X 9=16383 X 3 X 2=18
# samples 173
** MAII scorelog2(17/1638*10)=-3.26832870550331
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(3/18*10)=0.736965594166206
effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs).
DoF>8 and MAII>0
Fusion gene context

PubMed: AKAP8 [Title/Abstract] AND OSGEPL1 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: AKAP8 [Title/Abstract] AND OSGEPL1 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)AKAP8(15472539)-OSGEPL1(190618790), # samples:1
Anticipated loss of major functional domain due to fusion event.AKAP8-OSGEPL1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
AKAP8-OSGEPL1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
AKAP8-OSGEPL1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
AKAP8-OSGEPL1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID


check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr19:15472539/chr2:190618790)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across AKAP8 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across OSGEPL1 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000269701AKAP8chr1915472539-ENST00000264151OSGEPL1chr2190618790-24251457371887616
ENST00000269701AKAP8chr1915472539-ENST00000519810OSGEPL1chr2190618790-25161457371737566
ENST00000269701AKAP8chr1915472539-ENST00000522700OSGEPL1chr2190618790-18881457371887617

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000269701ENST00000264151AKAP8chr1915472539-OSGEPL1chr2190618790-0.0021041180.99789584
ENST00000269701ENST00000519810AKAP8chr1915472539-OSGEPL1chr2190618790-0.0021389880.99786097
ENST00000269701ENST00000522700AKAP8chr1915472539-OSGEPL1chr2190618790-0.0063198270.9936801

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for AKAP8-OSGEPL1

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
AKAP8chr1915472539OSGEPL1chr21906187901457473EKETAKPKPDPFKGIEKGQILSSAAD

Top

Potential FusionNeoAntigen Information of AKAP8-OSGEPL1 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
AKAP8-OSGEPL1_15472539_190618790.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
AKAP8-OSGEPL1chr1915472539chr21906187901457HLA-C03:17KGIEKGQIL0.99560.85481221
AKAP8-OSGEPL1chr1915472539chr21906187901457HLA-C03:67KGIEKGQIL0.99070.96221221
AKAP8-OSGEPL1chr1915472539chr21906187901457HLA-B07:13KGIEKGQIL0.28970.55341221
AKAP8-OSGEPL1chr1915472539chr21906187901457HLA-B51:09DPFKGIEKGQI0.98210.5055920

Top

Potential FusionNeoAntigen Information of AKAP8-OSGEPL1 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
AKAP8-OSGEPL1_15472539_190618790.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-0801PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-0801KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-0802PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-0803PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-0805PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-0805KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-0807PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-0807KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-0807PKPDPFKGIEKGQIL621
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-0808PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-0808KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-0808PKPDPFKGIEKGQIL621
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-0809PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-0811PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-0811KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-0811PKPDPFKGIEKGQIL621
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-0813PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-0814PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-0815PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-0816PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-0816KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-0819PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-0819KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-0821PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-0823PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-0824PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-0825PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-0825KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-0825PKPDPFKGIEKGQIL621
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-0826PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-0826KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-0827PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-0829PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-0829KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-0830PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-0833PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-0834PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-0834KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-0835PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-0836PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-0837PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-0837KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-0838PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-0839PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-0839KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1101PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1101KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1105PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1105KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1108PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1108KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1109PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1109KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1110PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1110KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1112PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1112KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1115PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1115KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1119PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1119KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1124PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1124KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1127PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1127KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1128PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1128KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1129PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1129KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1131PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1131KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1132PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1133PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1133KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1137PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1137KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1139PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1139KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1145PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1149PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1149KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1151PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1151KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1153PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1153KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1161PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1161KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1162PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1162KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1164PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1164KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1166PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1166KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1169PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1169KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1172PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1172KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1173PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1173KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1174PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1174KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1175PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1175KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1180PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1180KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1181PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1181KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1182PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1187PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1187KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1190PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1190KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1191PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1191KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1193PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1193KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1194PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1194KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1195PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1195KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1196PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1196KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1216PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1305PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1305KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1307PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1307KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-13100PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-13100KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-13100PKPDPFKGIEKGQIL621
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-13100DPFKGIEKGQILSSA924
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-13101PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-13101KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1310PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1310KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1313PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1314PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1314KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1321PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1321KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1326PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1326KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1330PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1330KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1331PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1331KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1337PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1346PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1346KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1346PKPDPFKGIEKGQIL621
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1346DPFKGIEKGQILSSA924
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1347PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1347KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1349PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1349KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1350PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1350KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1355PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1355KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1356PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1356KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1360PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1360KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1362PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1362KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1366PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1382PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1382KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1385PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1386PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1386KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1402PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1402KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1403PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1403KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1407PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1407KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1407PKPDPFKGIEKGQIL621
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1407DPFKGIEKGQILSSA924
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1407KPKPDPFKGIEKGQI520
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1409PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1409KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1413PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1413KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1414PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1414KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1414PKPDPFKGIEKGQIL621
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1422PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1422KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1422PKPDPFKGIEKGQIL621
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1424PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1425PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1425KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1425PKPDPFKGIEKGQIL621
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1427PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1427KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1430PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1430KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1436PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1436KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1436PKPDPFKGIEKGQIL621
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1440PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1440KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1441PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1441KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1442PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1442KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1442PKPDPFKGIEKGQIL621
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1444PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1444KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1444PKPDPFKGIEKGQIL621
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1448PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1448KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1449PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1449KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1449PKPDPFKGIEKGQIL621
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1451PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1451KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1453PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1453KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1453PKPDPFKGIEKGQIL621
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1463PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1463KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1467PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1468PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1468KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1468PKPDPFKGIEKGQIL621
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1468DPFKGIEKGQILSSA924
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1468KPKPDPFKGIEKGQI520
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1469PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1469KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1469PKPDPFKGIEKGQIL621
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1470PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1471PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1473PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1477PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1477KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1485PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1485KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1489PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1493PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1493KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1493PKPDPFKGIEKGQIL621
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1494PDPFKGIEKGQILSS823
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1494KPDPFKGIEKGQILS722
AKAP8-OSGEPL1chr1915472539chr21906187901457DRB1-1498PDPFKGIEKGQILSS823

Top

Fusion breakpoint peptide structures of AKAP8-OSGEPL1

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
6735PKPDPFKGIEKGQIAKAP8OSGEPL1chr1915472539chr21906187901457

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of AKAP8-OSGEPL1

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN6735PKPDPFKGIEKGQI-5.56647-5.67987
HLA-B14:023BVN6735PKPDPFKGIEKGQI-4.68492-5.72022
HLA-B52:013W396735PKPDPFKGIEKGQI-5.81993-5.93333
HLA-B52:013W396735PKPDPFKGIEKGQI-4.49544-5.53074
HLA-A11:014UQ26735PKPDPFKGIEKGQI-6.51126-7.54656
HLA-A24:025HGA6735PKPDPFKGIEKGQI-6.33559-6.44899
HLA-A24:025HGA6735PKPDPFKGIEKGQI-5.47048-6.50578
HLA-B44:053DX86735PKPDPFKGIEKGQI-6.87808-6.99148
HLA-B44:053DX86735PKPDPFKGIEKGQI-5.50513-6.54043

Top

Vaccine Design for the FusionNeoAntigens of AKAP8-OSGEPL1

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
AKAP8-OSGEPL1chr1915472539chr21906187901221KGIEKGQILAAGGTATTGAGAAGGGGCAAATCCTGT
AKAP8-OSGEPL1chr1915472539chr2190618790920DPFKGIEKGQIATCCTTTCAAAGGTATTGAGAAGGGGCAAATCC

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
AKAP8-OSGEPL1chr1915472539chr2190618790520KPKPDPFKGIEKGQIAACCAAAACCAGATCCTTTCAAAGGTATTGAGAAGGGGCAAATCC
AKAP8-OSGEPL1chr1915472539chr2190618790621PKPDPFKGIEKGQILCAAAACCAGATCCTTTCAAAGGTATTGAGAAGGGGCAAATCCTGT
AKAP8-OSGEPL1chr1915472539chr2190618790722KPDPFKGIEKGQILSAACCAGATCCTTTCAAAGGTATTGAGAAGGGGCAAATCCTGTCTT
AKAP8-OSGEPL1chr1915472539chr2190618790823PDPFKGIEKGQILSSCAGATCCTTTCAAAGGTATTGAGAAGGGGCAAATCCTGTCTTCAG
AKAP8-OSGEPL1chr1915472539chr2190618790924DPFKGIEKGQILSSAATCCTTTCAAAGGTATTGAGAAGGGGCAAATCCTGTCTTCAGCAG

Top

Information of the samples that have these potential fusion neoantigens of AKAP8-OSGEPL1

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
BLCAAKAP8-OSGEPL1chr1915472539ENST00000269701chr2190618790ENST00000264151TCGA-DK-A3IU

Top

Potential target of CAR-T therapy development for AKAP8-OSGEPL1

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to AKAP8-OSGEPL1

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to AKAP8-OSGEPL1

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource